GoodRx (NASDAQ:GDRX) Given New $8.00 Price Target at Wells Fargo & Company

GoodRx (NASDAQ:GDRX) had its price objective cut by research analysts at Wells Fargo & Company from $9.00 to $8.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price indicates a potential upside of 60.64% from the company’s previous close.

A number of other brokerages have also recently weighed in on GDRX. Barclays reduced their price target on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Monday, November 11th. Mizuho started coverage on shares of GoodRx in a research report on Wednesday, December 4th. They set a “neutral” rating and a $5.00 price target on the stock. Morgan Stanley reduced their price target on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Tuesday, December 17th. KeyCorp reduced their price target on shares of GoodRx from $7.00 to $6.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th. Finally, Citigroup reduced their price target on shares of GoodRx from $7.00 to $6.25 and set a “buy” rating on the stock in a research report on Friday, January 10th. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, GoodRx presently has an average rating of “Moderate Buy” and an average target price of $8.18.

GoodRx Price Performance

GDRX opened at $4.98 on Friday. The company has a fifty day moving average price of $4.71 and a two-hundred day moving average price of $5.74. The firm has a market capitalization of $1.90 billion, a PE ratio of -166.00, a P/E/G ratio of 2.46 and a beta of 1.28. GoodRx has a 52 week low of $4.09 and a 52 week high of $9.26. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48.

Institutional Trading of GoodRx

A number of institutional investors and hedge funds have recently made changes to their positions in GDRX. National Bank of Canada FI lifted its holdings in shares of GoodRx by 34.9% during the 4th quarter. National Bank of Canada FI now owns 8,308 shares of the company’s stock worth $39,000 after acquiring an additional 2,151 shares during the period. RPO LLC bought a new stake in shares of GoodRx during the 4th quarter worth approximately $52,000. Versor Investments LP bought a new stake in shares of GoodRx during the 4th quarter worth approximately $54,000. Verus Capital Partners LLC bought a new stake in shares of GoodRx during the 4th quarter worth approximately $55,000. Finally, Steward Partners Investment Advisory LLC acquired a new position in GoodRx during the 4th quarter worth approximately $56,000. Institutional investors own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.